Medication-assisted treatment for opioid dependence: Making a difference in prisons

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Pecoraro, Anna ^a,b   Woody, George E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Delaware Valley Node   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; COCAINE; METHADONE; OPIATE;

EVIDENCE BASED PRACTICE; HUMAN; OPIATE ADDICTION; PRISON; REVIEW;

EID: 79551692302     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-1     Document Type: Review

References (37)

1. th Edition. London: International Centre for Prison Studies, King's College; 2008. [http://www.kcl.ac.uk/depsta/law/research/icps/downloads/wppl-8th-41.pdf]
2. Bureau of Justice Statistics: Total correctional population. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2008.
3. Mumola CJ, Karberg JC: Drug use and dependence, state and federal prisoners, 2004. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2006.
4. Chaiken JM: Correctional Population of the United States, 1997. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2000.
5. Karberg JC, James DJ: Substance dependence, abuse, and treatment of jail inmates, 2002. Bureau of Justice Statistics Special Report. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 2005.
6. Beck A, Gillard D, Greenfeld L, Harlow C, Hester T, Jankowski L, Morton DC, Snell TL, Stephan JJ: Survey of state prison inmates, 1991. Washington, DC: Office of Justice Programs, Bureau of Justice Statistics; 1993.
7. European Monitoring Centre for Drugs and Drug Addiction: Annual Report 2009: The state of the drug problem in Europe. Luxembourg: Publications Office of the European Union; 2009. [http://www.emcdda.europa.eu/attachements.cfm/att- 93236-EN-EMCDDA-AR2009-EN.pdf]
8. Jürgens R, WHO, UNODC, UNAIDS: Evidence for action technical papers: Interventions to address HIV in prisons. Drug dependence treatments. Geneva: WHO; 2007. [http://whqlibdoc.who.int/publications/2007/9789241595803-eng.pdf]
9. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009, 3:CD002209.
10. Schulte B, Thane K, Rehm J, Uchtenhagen A, Stöver H, Degkwitz P, Reimer J, Haasen C: Review of the efficacy of drug treatment interventions in Europe: Drug Policy and Harm Reduction Report. Hamburg: Center for Interdisciplinary Addiction Research of Hamburg University; 2008.
11. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E: Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: An 18 month prospective follow-up. J Acquir Immune Defic Syndr 1993, 6:1049-56. (Pubitemid 23239778)
12. Emmanuelli J, Desenclos JC: Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 2005, 100:1690-700.
13. Lind B, Chen S, Weatherburn D, Mattick R: The effectiveness of methadone maintenance in controlling crime: An Australian aggregate-level analysis. Br J Criminol 2005, 45:201-11. (Pubitemid 41236930)
14. Gibson A, Degenhardt L, Mattick RP, Alin R, White J, O'Brien S: Exposure to opioid maintenance treatment reduces longterm mortality. Addiction 2008, 103:462-8. (Pubitemid 351208102)
15. WHO: WHO Guidelines on HIV and AIDS in Prisons. Geneva: WHO; 1999, [http://data.unaids.org/Publications/IRC-pub01/jc277-whoguidel-prisons-en.pdf]
16. WHO: Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO; 1999. [http://www.who.int/ substance-abuse/publications/opioid-dependence-guidelines.pdf]
17. UNODC/WHO/UNAIDS: HIV/AIDS prevention, care, treatment, and support in prison settings. Vienna: UN Office on Drugs and Crime; 2006. [http://data.unaids.org/pub/Report/2006/20060701-hiv-aids-prisons-en.pdf]
18. Larney S, Dolan K: A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Eur Addict Res 2009, 15:107-12.
19. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD: Methadone and bupreorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug Alcohol Depend 2009, 105:83-8.
20. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD: Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health 2005, 82:411-9. (Pubitemid 41191560)
21. WHO: Neuroscience of psychoactive substance use and dependence. Geneva: WHO; 2004. [http://www.who.int/substance-abuse/publications/en/Neuroscience.pdf]
22. Chandler RK, Fletcher BW, Volkow ND: Treating drug abuse and addiction in the criminal justice system: Improving public health and safety. JAMA 2009, 301:183-90.
23. McLellan AT, Lewis DC, O'Brien CP, Kleber HD: Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-95.
24. Uhi GR, Grow RW: The burden of complex genetics in brain disorders. Arch Gen Psychiatry 2004, 61:223-9.
25. Dole V, Robinson J, Orraca J, Towns E, Searcy P, Caine E: Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969, 280:1372-5.
26. Tomasino V, Swanson AJ, Nolan J, Shuman H: The Key Extended Entry Program KEEP: a methadone treatment program for opiate-dependent inmates. Mt Sinai J Med 2001, 68:14-20. (Pubitemid 32063464)
27. Gordon MS, Kinlock TW, Schwartz RP, O'Grady KE: A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction 2008, 103:1333-42.
28. Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE: A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months postrelease. J Subst Abuse Treat 2009, 37:277-85.
29. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD: A randomized controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 2003, 72:59-65.
30. Wale S, Gorta A: Views of inmates participating in the pilot pre-release methadone program. Process evaluation of New South Wales Department of Corrective Services pre-release methadone program study No 2. Sydney: Research and Statistics Division, New South Wales Department of Corrective Services; 1987.
31. Dolan K, Hall W, Wodak A: Methadone maintenance reduces injecting in prison. BMJ 1996, 312:1162.
32. Magura S, Rosenblum A, Lewis C, Joseph H: The effectiveness of injail methadone maintenance. J Drug Issues 1993, 23:75-9.
33. Branch CR: Institutional methadone maintenance treatment: Impact on release outcome and institutional behavior. Ottawa: Correctional Service Canada; 2002.
34. Larney S: Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction 2010, 105:216-23.
35. Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, Rosenblum A: Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug Alcohol Depend 2009, 99:222-30.
36. Albizu-Garcia C, Caraballo Correa G, Hernandez Viver AD, Kinlock TW, Gordon MS, Antron Avila C: Buprenorphinenaloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addict Med 2007, 1:126-32.
37. Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT: Developing and implementing a new prison-based buprenorphine treatment program. J Offender Rehabil 2010, 49:91-109.